title: Tamoxifen-encapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line.
abstract: OBJECTIVE
  Tamoxifen is a nonsteroidal estrogen receptor modulator indicated in the treatment of breast cancer. Apoptosis has been reported to be a major mechanism for its antitumor effect. Tamoxifen has also shown significant potential in treating various dermatological disorders including psoriasis, characterized by hyperproliferation of epidermal keratinocytes. An endeavor was made in the current studies to investigate the potency of vesicle-encapsulated tamoxifen on human epidermal keratinocyte cell lines.
  
  
  METHODS
  Drug was encapsulated in the phospholipid-based vesicular systems, namely, conventional liposomes and flexible-membrane liposomes. In vitro cytotoxicity evaluation of the formulations was carried out employing MTT cell proliferation assay.
  
  
  RESULTS
  A composition-dependent strong inhibition in the viability of epidermal keratinocyte cells was observed.
  
  
  CONCLUSIONS
  The encouraging findings of this work construe immense potential of the tamoxifen-encapsulated vesicular systems in the management of psoriasis.
authors.affiliation: Drug Delivery Research Group, University Institute of Pharmaceutical Sciences-UGC Centre of Advanced Study, Panjab University, Chandigarh, India.
authors.forename: Amit
authors.initials: A
authors.lastname: Bhatia
authors.forename: Bhupinder
authors.initials: B
authors.lastname: Singh
authors.forename: Shashi
authors.initials: S
authors.lastname: Bhushan
authors.forename: Om Prakash
authors.initials: OP
authors.lastname: Katare
mesh_terms: D000279:Administration, Cutaneous; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002784:Cholesterol / Q000737:chemistry; D004337:Drug Carriers / Q000008:administration & dosage* / Q000494:pharmacology; D006601:Hexoses / Q000737:chemistry; D006801:Humans; D020128:Inhibitory Concentration 50; D015603:Keratinocytes / Q000187:drug effects; D008081:Liposomes; D008560:Membrane Fluidity; D010713:Phosphatidylcholines / Q000737:chemistry; D011565:Psoriasis / Q000188:drug therapy; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage* / Q000494:pharmacology; D013501:Surface-Active Agents / Q000737:chemistry; D013629:Tamoxifen / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D004337:Drug Carriers; D006601:Hexoses; D008081:Liposomes; D010713:Phosphatidylcholines; D020845:Selective Estrogen Receptor Modulators; D013501:Surface-Active Agents; C018665:sorbitan monooleate; D013629:Tamoxifen; D002784:Cholesterol